Corrigendum to “Metformin inhibits the pathogenic functions of AChR-specifc B and Th17 cells by targeting miR-146a” [Immunology Letters 250 (2022) 29–40 on Sep 13, 2022/ Manuscript ID: IMLET-D-22-00159R2, PMID: 36108773]

IF 3.3 4区医学 Q3 IMMUNOLOGY

Immunology letters Pub Date : 2024-05-24 DOI:10.1016/j.imlet.2024.106866

Yue Hao , Wei Zhao , Lulu Chang , Xingfan Chen , Chonghui Liu , Yang Liu , Lixuan Hou , Yinchun Su , Hao Xu , Yu Guo , Qixu Sun , Lili Mu , Jinghua Wang , Hulun Li , Junwei Han , Qingfei Kong

引用次数: 0

查看原文本刊更多论文

二甲双胍通过靶向 miR-146a 抑制 AChR-specifc B 细胞和 Th17 细胞的致病功能》的更正 [Immunology Letters 250 (2022) 29-40 on Sep 13, 2022/ Manuscript ID：IMET-D-22-00159R2, PMID: 36108773]

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunology letters 医学-免疫学

CiteScore

7.60

自引率

0.00%

发文量

审稿时长

44 days

期刊介绍： Immunology Letters provides a vehicle for the speedy publication of experimental papers, (mini)Reviews and Letters to the Editor addressing all aspects of molecular and cellular immunology. The essential criteria for publication will be clarity, experimental soundness and novelty. Results contradictory to current accepted thinking or ideas divergent from actual dogmas will be considered for publication provided that they are based on solid experimental findings. Preference will be given to papers of immediate importance to other investigators, either by their experimental data, new ideas or new methodology. Scientific correspondence to the Editor-in-Chief related to the published papers may also be accepted provided that they are short and scientifically relevant to the papers mentioned, in order to provide a continuing forum for discussion.